125 related articles for article (PubMed ID: 9375737)
1. Sickle cell disease: relation between procoagulant activity of red blood cells from different phenotypes and in vivo blood coagulation activation.
Helley D; Girot R; Guillin MC; Bezeaud A
Br J Haematol; 1997 Nov; 99(2):268-72. PubMed ID: 9375737
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
Whelihan MF; Lim MY; Mooberry MJ; Piegore MG; Ilich A; Wogu A; Cai J; Monroe DM; Ataga KI; Mann KG; Key NS
J Thromb Haemost; 2016 Oct; 14(10):1941-1952. PubMed ID: 27430959
[TBL] [Abstract][Full Text] [Related]
3. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia.
Helley D; Eldor A; Girot R; Ducrocq R; Guillin MC; Bezeaud A
Thromb Haemost; 1996 Sep; 76(3):322-7. PubMed ID: 8883264
[TBL] [Abstract][Full Text] [Related]
4. Thrombophilia in sickle cell disease: the red cell connection.
Setty BN; Rao AK; Stuart MJ
Blood; 2001 Dec; 98(12):3228-33. PubMed ID: 11719358
[TBL] [Abstract][Full Text] [Related]
5. Enhanced thrombin generation in children with sickle cell disease.
Peters M; Plaat BE; ten Cate H; Wolters HJ; Weening RS; Brandjes DP
Thromb Haemost; 1994 Feb; 71(2):169-72. PubMed ID: 8191393
[TBL] [Abstract][Full Text] [Related]
6. Coagulation changes in individuals with sickle cell trait.
Westerman MP; Green D; Gilman-Sachs A; Beaman K; Freels S; Boggio L; Allen S; Schlegel R; Williamson P
Am J Hematol; 2002 Feb; 69(2):89-94. PubMed ID: 11835343
[TBL] [Abstract][Full Text] [Related]
7. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation.
Setty BN; Kulkarni S; Rao AK; Stuart MJ
Blood; 2000 Aug; 96(3):1119-24. PubMed ID: 10910931
[TBL] [Abstract][Full Text] [Related]
8. Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.
Hyacinth HI; Adams RJ; Greenberg CS; Voeks JH; Hill A; Hibbert JM; Gee BE
PLoS One; 2015; 10(8):e0134193. PubMed ID: 26305570
[TBL] [Abstract][Full Text] [Related]
9. Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C.
Bezeaud A; Venisse L; Helley D; Trichet C; Girot R; Guillin MC
Br J Haematol; 2002 May; 117(2):409-13. PubMed ID: 11972526
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays.
Noubouossie DC; Lê PQ; Rozen L; Debaugnies F; Ferster A; Demulder A
Thromb Res; 2012 Aug; 130(2):259-64. PubMed ID: 22079446
[TBL] [Abstract][Full Text] [Related]
11. Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.
Averett RD; Norton DG; Fan NK; Platt MO
J Thromb Thrombolysis; 2017 Jan; 43(1):43-51. PubMed ID: 27664114
[TBL] [Abstract][Full Text] [Related]
12. Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine.
Bonomini M; Sirolli V; Merciaro G; Antidormi T; Di Liberato L; Brummer U; Papponetti M; Cappelli P; Di Gregorio P; Arduini A
Nephrol Dial Transplant; 2005 Feb; 20(2):361-6. PubMed ID: 15598665
[TBL] [Abstract][Full Text] [Related]
13. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients.
Atichartakarn V; Angchaisuksiri P; Aryurachai K; Onpun S; Chuncharunee S; Thakkinstian A; Atamasirikul K
Br J Haematol; 2002 Sep; 118(3):893-8. PubMed ID: 12181063
[TBL] [Abstract][Full Text] [Related]
14. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
Head CA; Brugnara C; Martinez-Ruiz R; Kacmarek RM; Bridges KR; Kuter D; Bloch KD; Zapol WM
J Clin Invest; 1997 Sep; 100(5):1193-8. PubMed ID: 9276736
[TBL] [Abstract][Full Text] [Related]
15. Human endothelial cells suppress prothrombin activation in nonanticoagulated whole blood in vitro.
Biedermann B; Rosenmund A; Muller M; Kohler HP; Haeberli A; Straub PW
J Lab Clin Med; 1994 Sep; 124(3):339-47. PubMed ID: 8083577
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Gordeuk VR; Gladwin MT
Am J Hematol; 2023 Jul; 98(7):1017-1028. PubMed ID: 36971592
[TBL] [Abstract][Full Text] [Related]
17. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
Eisenberg PR; Siegel JE; Abendschein DR; Miletich JP
J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759
[TBL] [Abstract][Full Text] [Related]
18. Hypercoagulable state in sickle cell disease.
Faes C; Sparkenbaugh EM; Pawlinski R
Clin Hemorheol Microcirc; 2018; 68(2-3):301-318. PubMed ID: 29614638
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India.
Nishank SS; Singh MP; Yadav R
Eur J Haematol; 2013 Nov; 91(5):462-6. PubMed ID: 23992124
[TBL] [Abstract][Full Text] [Related]
20. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
Kurantsin-Mills J; Ofosu FA; Safa TK; Siegel RS; Lessin LS
Br J Haematol; 1992 Aug; 81(4):539-44. PubMed ID: 1390242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
